Monday, December 03, 2018 10:09:29 AM
Nash Pharmaceuticals Announces Positive Pre-Clinical Results Showing Lead Compound NP-160 Significantly Reduces NALFD Score and Fibrosis in Non-Alcoholic Fatty Liver Disease
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in Inflammatory Bowel Disease
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-135 in Chronic Kidney Disease
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in a New Study for Crohn’s Disease
http://breathtecbiomedical.com/news/corporate-news/
GATLING GUN
/////AMG
Red Pills
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
